Advertisement


Lawrence N. Shulman, MD, and Daniel A. Goldstein, MD: Expert Perspectives on Issues in Global Cancer Care

2016 ASCO Annual Meeting

Advertisement

Lawrence N. Shulman, MD, of Abramson Cancer Center at the University of Pennsylvania, and Daniel A. Goldstein, MD, of the Rabin Medical Center, discuss global challenges in cancer care, including treating patients in areas lacking resources, and cancer drug price disparities (Abstract LBA6500).



Related Videos

Integrative Oncology
Palliative Care

Eric Roeland, MD, and Jennifer S. Temel, MD, on Integrative Palliative and Oncology Care

Eric Roeland, MD, of the University of California, San Diego, and Jennifer S. Temel, MD, of Massachusetts General Hospital, discuss findings that showed the benefits of offering palliative care integrated with oncology care (Abstracts 10003 and 10131).

Gastrointestinal Cancer
Gastroesophageal Cancer

Salah-Eddin Al-Batran, MD, on Gastric and GEJ Adenocarcinoma: Results From the FAST Trial

Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses findings from this international phase II study of epirubicin, oxaliplatin, and capecitabine with or without IMAB362, as first-line treatment of gastric and gastroesophageal junction adenocarcinoma (Abstract LBA4001).

CNS Cancers

Martin J. Van Den Bent, MD, PhD, on Anaplastic Glioma: Results from the CATNON Trial

Martin J. Van Den Bent, MD, PhD, of the Daniel den Hoed Cancer Center, discusses the interim analysis of the EORTC phase III study on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion (Abstract LBA2000).

CNS Cancers

James R. Perry, MD, on Glioblastoma: Study Results on Treating Elderly Patients

James R. Perry, MD, of Sunnybrook Health Sciences Centre, discusses findings of a phase III trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in older patients with this tumor (Abstract LBA2).

Skin Cancer

Anthony J. Olszanski, RPh, MD, and Michael A. Davies, MD, PhD, on the COMBI-d Study on Cutaneous Melanoma

Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Michael A. Davies, MD, PhD, of the University of Texas MD Anderson Cancer Center, discuss this phase III study of dabrafenib plus trametinib vs dabrafenib monotherapy in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma (Abstract 9502).

Advertisement

Advertisement




Advertisement